"For treatment of acute lymphoblastic leukemia"@en . "130167-69-0"@en . . . . . "approved"@en . "Humans and other mammals"@en . . "investigational"@en . "Pegaspargase, more effective than asparaginase, converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death."@en . . "IM: ~6 days; half-life decreased to ~3 days (range: 1.4 to 5 days) in patients with previous hypersensitivity to native L-asparaginase; IV: Adults (asparaginase naive): 7 days"@en . "L-asparagine amidohydrolase"@en . . . " "@en . "Onset of Asparagine depletion by IM is within 4 days Time to peak: IM: 3 to 4 days"@en . "Pegaspargase"@en . " IV: Adults (asparaginase naive): 2.4 L/m2 Distributes into CSF (reportedly reducing CSF asparagine concentrations to a similar extent as asparaginase"@en . "Pegylated L-asparagine amidohydrolase from E. coli. Pegylation substantially (by a factor of 4) extends the protein half life."@en . . . "Adverse effects that occur more than 10% of the time include hepatotoxicity as it is known to increase serum transaminases (ALT, AST). Also known to induce hypersensitivity reactions including anaphylaxis, erythema and bronchospasm. "@en . "# Graham ML: Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14499708 #Lexicomp Online (2014). Pegaspargase. Available at:http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7445#f_adverse-reactions [Accessed 12 Nov. 2014]. #American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Pegaspargase; [updated 2013 Jan 18; cited 2014 Nov 12]. Available from http://search.ebscohost.com/login.aspx?direct=true&site=DynaMed&id=233015."@en . . . . "Putative L-asparaginase precursor"@en . . . . . . . . .